ATRC logo

ATRICURE INC

ATRCNASDAQ
πŸ† #1704 by market capEarnings Oct 27 Β· PostUS Equity
$57.37β–Ό $0.67 (βˆ’1.17%)
Live
πŸ””
Track ATRC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.2%
7dβ–Ό 4.2%
14dβ–² 0.4%
30dβ–² 18.7%
ytdβ–² 45.2%
1yβ–² 62.7%
🏦Market Cap
$2.92B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+14.9%
Healthy
πŸ“ŠGross Margin
76.2%
High
πŸ’΅FCF Margin
10.2%
Healthy
βš–οΈP/S Ratio
5.2x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$57.13 – $58.41
52-Week Range
$25.36 – $61.70
Volume
$5.94B
Avg Volume
$6.42B
Shares Outstanding
50.9M
Next Earnings
Dec 5, 2026

Fundamentals Snapshot

Annual Revenue
$535M
Last Q Revenue
$154M
P/E Ratio
275.3
P/S Ratio
5.2x
EPS (TTM)
$0.22
Dividend Yield
0.00%
Dilution (1yr)
+3.8%

Why Investors Own ATRC

  • βœ“High-growth profile β€” revenue up -5.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 49% gross margin and 29% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ATRC logo

ATRICURE INC

ATRC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$535Mβ–² +14.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.4%β–Ό βˆ’0.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$3Mβ–Ό βˆ’91.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$48Mβ–Ό βˆ’529.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.9Mβ–² +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79Mβ–² +$33M YoY
StockOtter Β· stockotter.space

About ATRICURE INC

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
16 analysts
Strong Buy4
Buy9
Hold3
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates